{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Chang CY"],"funding":["NHLBI NIH HHS"],"pubmed_abstract":["During red blood cell (RBC) transfusion, production of alloantibodies can promote significant hemolytic events. However, most transfusion recipients do not form anti-RBC alloantibodies. Identifying mechanisms that inhibit alloimmunization may lead to prophylactic interventions. One potential regulatory mechanism is activation of the transcription factor, nuclear factor erythroid-derived 2-like 2 (Nrf2), a master regulatory of antioxidant pathways. Pharmacologic Nrf2 activators improve sequelae of sickle cell disease in pre-clinical models. The Nrf2 activator, 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im), suppresses production of inflammatory cytokines including type 1 interferons (IFNα/β), which have been implicated in promoting RBC alloimmunization in transfusion m"],"journal":["bioRxiv : the preprint server for biology"],"pagination":["2025.04.03.645598"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11996576"],"repository":["biostudies-literature"],"pubmed_title":["CDDO-Imidazole regulates RBC alloimmunization to the KEL antigen by activating Nrf2."],"pmcid":["PMC11996576"],"funding_grant_id":["R01 HL165169"],"pubmed_authors":["Nance K","Paul K","Shibata T","Yue P","Stehlik C","Gibb DR","Chang CY","Hernandez-Armengol R","Lee JY"],"additional_accession":[]},"is_claimable":false,"name":"CDDO-Imidazole regulates RBC alloimmunization to the KEL antigen by activating Nrf2.","description":"During red blood cell (RBC) transfusion, production of alloantibodies can promote significant hemolytic events. However, most transfusion recipients do not form anti-RBC alloantibodies. Identifying mechanisms that inhibit alloimmunization may lead to prophylactic interventions. One potential regulatory mechanism is activation of the transcription factor, nuclear factor erythroid-derived 2-like 2 (Nrf2), a master regulatory of antioxidant pathways. Pharmacologic Nrf2 activators improve sequelae of sickle cell disease in pre-clinical models. The Nrf2 activator, 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im), suppresses production of inflammatory cytokines including type 1 interferons (IFNα/β), which have been implicated in promoting RBC alloimmunization in transfusion m","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-05-07T03:18:38.704Z","creation":"2026-05-07T03:08:56.303Z"},"accession":"S-EPMC11996576","cross_references":{"pubmed":["40235992"],"doi":["10.1101/2025.04.03.645598"]}}